Top of this page
Skip navigation, go straight to the content

Investors UCB Governance

UCB Governance

 The Company is administered by a Board of Directors and run by an Executive Committee, whose respective functions and responsibilities are clearly defined in the Corporate Governance Charter.

The General Meeting of Shareholders is convened once a year, on the last Thursday of April, for its Ordinary meeting. A General Meeting of Shareholders may also be called in Special or Extraordinary circumstances whenever the Company interests dictate. Rules relating to General Meetings and main rights and obligations of Shareholders are further detailed in the Corporate Governance Charter.

 

Board of Directors

 

UCB Board and Committees

To enhance the overall effectiveness of the Board by ensuring focus, oversight and monitoring of sensitive areas, the Board has created three specialist committees:

Board of Directors

  • 13 members
  • 7 independent directors (54%)
  • 5 nationalities
  • 4 women (31%)
  • 4-year mandate
  • age limit: 70

 

Executive Committee

  • 12 members
  • 6 nationalities
  • 3 women (25%)

 

Members of Board of Directors

Evelyn du Monceau

Chair of the Board

Gerhard Mayr

First appointed in 1984

End of term in 2019

Chair of the GNCC

Pierre Gurdjian

Vice Chairman & Independent Director

image description

First appointed in 2016

End of term in 2020

Member of the GNCC

Jean-Christophe Tellier

Executive Director

image description

First appointed in 2014

End of term in 2022

 

Alice Dautry

Independent Director

image description

First appointed in 2015

End of term in 2019

Member of the Scientific Committee

 

Kay Davies

Independent Director

image description

First appointed in 2014

End of term in 2022

Chair of the Scientific Committee

Member of the GNCC

Albrecht De Graeve

Independent Director

image description

First appointed in 2010

End of term in 2021

Chairman of the Audit Committee

 

Roch Doliveux

Director

image description

Appointed in 2017

End of term in 2021

 

Charles-Antoine Janssen

Director

image description

First appointed in 2012

End of term in 2020

Member of the Audit Committee

Cyril Janssen

Director

image description

First appointed in 2015

End of term in 2019

 

Viviane Monges

Independent Director

image description

First appointed in 2017

End of term in 2021

Norman J. Ornstein

Independent Director

image description

First appointed in 2008

End of term in 2019

Cédric van Rijckevorsel

Director

image description

First appointed in 2014

End of term in 2022

Ulf Wiinberg

Independent Director

image description

First appointed in 2016

End of term in 2020

Member of the Audit Committee

 

Members of the Executive Committee

We have adapted the organization structure on four pillars around which we are creating value for each patient, centered by our focus and integrated across functional teams around different patient populations.

UCB Patient Value Organization

Jean-Christophe Tellier

Jean-Christophe Tellier

Chief Executive Officer and
Chairman of the Executive Committee

Joined UCB in June 2011
Appointed as CEO in January 2015

Emmanuel Caeymaex

Emmanuel Cayemaex

Executive Vice President
Immunology Patient Value Unit Head

Joined UCB in March 1994
Appointed in February 2015

Jean Luc Fleurial

Iris Loew-Friedrich

Executive Vice President 
Chief Talent Officer

Joined UCB in September 2017
Appointed in September 2017

Iris Löw-Friedrich

Pascale Richetta

Executive Vice President
Chief Medical Officer

Joined UCB in September 2006
Appointed in March 2008

Alexander Moscho

image description

Executive Vice President
Chief Strategy Officer

Joined UCB in October 2017
Appointed in October 2017

Dhaval Patel 

image description

Executive Vice President
Chief Scientific Officer

Joined UCB in October 2017
Appointed in October 2017

Pascale Richetta

Pascale Richetta

Executive Vice President
Bone Patient Value Unit Head

Joined UCB in February 2016
Appointed in February 2016

Anna S. Richo

Anna S. Richo

Executive Vice President
General Counsel

Joined UCB in November 2012
Appointed in November 2012

Bharat Tewarie

Bharat Tewarie

Executive Vice President
Chief Marketing Officer

Joined UCB in March 2015
Appointed in March 2015

Detlef Thielgen

image description

Executive Vice President
Chief Financial Officer

Joined UCB in September 2006
Appointed in January 2007

Charl van Zyl

image description

Executive Vice President
Chief Operating Officer

Joined UCB in March 2017
Appointed in March 2017

Jeff Wren

image description

Executive Vice President
Neurology Patient Value Unit Head

Joined UCB in October 2010
Appointed in February 2015

Shareholders and shareholders meetings

Find out about UCB shareholders, their transparency notifications and our shareholders meetings on the dedicated webpage.

Main corporate governance documents

UCB has adopted the Belgian Code of Corporate Governance (second edition) published on March 2009 as its reference Code taking into account the specific international aspects of the Company. As part of these rules, UCB, as a publicly traded company, has adopted a Code of Business Conduct, including a Code of Share Dealing.

The Corporate Governance Charter established by the Board of Directors aims at providing a comprehensive and transparent disclosure of the Company’s governance. It defines the system of checks and balances between the shareholders/investors, the Board and the management to shape an efficiently functioning company, ideally geared to produce long-term, sustainable value. It will be continuously updated as required.

Articles of Association

Special reports of the Board